Abstract: A device may receive first information identifying multiple server devices and second information identifying multiple flows. The device may assign the multiple flows to the multiple server devices in a first order. The device may store the second information in multiple data structures to record the assignment of the multiple flows to the multiple server devices. A data structure, of the multiple data structures, may correspond to a respective server device of the multiple server devices. The device may receive an indication that a server device has been added to, or removed from, the multiple server devices after storing the second information. The device may reassign a subset of the multiple flows in a second order using third information identifying an order in which the multiple flows were assigned to the multiple server devices. The second order may be different from the first order.

Abstract: In one example, a network device is configured as a leaf node of an interconnected topology that defines a plurality of network paths from the network device to each of a plurality of other leaf nodes of the interconnected topology. The network device includes one or more processing units configured to forward a first packet of a packet flow along a first network path of the plurality of network paths, after receiving a second packet of the packet flow, determine an inactivity interval for the packet flow that represents an amount of time between receipt of the first packet and receipt of the second packet, compare the inactivity interval to a threshold, and when the inactivity interval is greater than the threshold, forward the second packet along a second network path of the plurality of network paths, wherein the second network path is different than the first network path.

Abstract: In some embodiments, a method includes defining, by a processor included in a first node, a virtual-extensible-local-area-network (VXLAN) tunnel between the first node included in a first layer-two network, and a second node included in a second layer-two network, the VXLAN tunnel traversing at least one node of a layer-three network. The method includes receiving, at the first node, a layer-two data unit that is sent from a third node included in the first layer-two network, to a fourth node included in the second layer-two network. The method includes encapsulating, at the first node, the layer-two data unit to define an encapsulated data unit that includes a VXLAN header. The method includes sending the encapsulated packet from the first node towards the fourth node via the VXLAN tunnel.

Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

Abstract: The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which inhibit the level of PK220 gene expression or activity, wherein a desired phenotype such as increased water use efficiency relative to a wild type control plant. The invention also relates to nucleic acid sequences and constructs useful such methods and methods of generating and isolating plants having decreased PK220 expression or activity.

Abstract: Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

Abstract: A device may receive first information identifying multiple server devices and second information identifying multiple flows. The device may assign the multiple flows to the multiple server devices in a first order. The device may store the second information in multiple data structures to record the assignment of the multiple flows to the multiple server devices. A data structure, of the multiple data structures, may correspond to a respective server device of the multiple server devices. The device may receive an indication that a server device has been added to, or removed from, the multiple server devices after storing the second information. The device may reassign a subset of the multiple flows in a second order using third information identifying an order in which the multiple flows were assigned to the multiple server devices. The second order may be different from the first order.

Abstract: The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which inhibit the level of PK220 gene expression or activity, wherein a desired phenotype such as increased water use efficiency relative to a wild type control plant. The invention also relates to nucleic acid sequences and constructs useful such methods and methods of generating and isolating plants having decreased PK220 expression or activity.

Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

Abstract: Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R2, R3, R4, p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Abstract: In one example, a plurality of network devices forming an Internet protocol (IP) fabric includes first, second, third, and fourth network devices. The first network device includes a plurality of network interfaces communicatively coupled to at least the third and fourth network devices of the plurality of network devices, which are between the first network device and the second network device. The first network device also includes one or more hardware-based processors configured to determine available bandwidths for the third network device and the fourth network device toward the second network device, determine a ratio between the available bandwidths for the third and fourth network devices, and forward data (e.g., packets or bytes) toward the second network device such that a ratio between amounts of the data forwarded to the third and fourth network devices corresponds to the ratio between the available bandwidths.

Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

Abstract: The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which increase the level of expression of a MYB-subgroup14 polynucleotide or a MYB68 polypeptide. The method also relates to expression of a nucleic acid sequence encoding a MYB-subgroup14 or a MYB68 transcriptional factor. The methods are directed to elevating the levels of a MYB-subgroup14 or a MYB68 expression, wherein a desired phenotype such as reduced flower abortion and increased yield during heat stress is observed. The invention also relates to nucleic acid sequences useful in such methods.

Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R2, R3, R4, p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Abstract: The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which inhibit the level of PK220 gene expression or activity, wherein a desired phenotype such as increased water use efficiency relative to a wild type control plant. The invention also relates to nucleic acid sequences and constructs useful such methods and methods of generating and isolating plants having decreased PK220 expression or activity.

Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R2, R3, R4, p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Abstract: The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which inhibit the level of PK220 gene expression or activity, wherein a desired phenotype such as increased water use efficiency relative to a wild type control plant. The invention also relates to nucleic acid sequences and constructs useful such methods and methods of generating and isolating plants having decreased PK220 expression or activity.

Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R2, R3, R4, p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.